Please enable JavaScript to continue using this application.

Compare $BBOT vs $SABS | Chartloom

Compare

$BBOT vs $SABS

BridgeBio Oncology Therapeutics Inc · SAB Biotherapeutics Inc

BBOT

BridgeBio Oncology Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Compare $BBOT vs $SABS

Comparing BridgeBio Oncology Therapeutics Inc and SAB Biotherapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

SABSSAB Biotherapeutics Inc

BBOTBridgeBio Oncology Therapeutics Inc

Market cap

$265M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-73.1%

52W performance

-72.5%

FCF yield

-73.1%

SABSSAB Biotherapeutics Inc

Market cap

$228M

P/E (TTM)

20.43x

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-21.0%

52W performance

27.4%

FCF yield

-25.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BBOT

SABS

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Market Cap

BBOT$265M

SABS$228M

Enterprise Value

BBOT$211M

SABS$223M

Price

BBOT$3.31

SABS$2.98

P/E Ratio

BBOTN/A

SABS20.43x

P/S Ratio

BBOT0.00x

SABS204.97x

EV/Sales

BBOT0.00x

SABS201.14x

EV/EBITDA

BBOT0.00x

SABS0.00x

P/B Ratio

BBOT0.97x

SABS1.26x

P/FCF Ratio

BBOTN/A

SABSN/A

EV/FCF

BBOT-1.09x

SABS-3.88x

PEG Ratio

BBOTN/A

SABSN/A

Forward P/E (NTM)

BBOTN/A

SABSN/A

Forward P/S (NTM)

BBOTN/A

SABSN/A

Revenue (TTM)

BBOT$0

SABS$0

Revenue Growth (YoY)

BBOTN/A

SABSN/A

Forward Rev Growth

BBOT540.3%

SABS13369.8%

Gross Margin (TTM)

BBOT0.0%

SABS0.0%

Operating Margin (TTM)

BBOT0.0%

SABS0.0%

EBITDA Margin (TTM)

BBOT0.0%

SABS0.0%

Net Margin (TTM)

BBOT0.0%

SABS0.0%

FCF Margin (TTM)

BBOTN/A

SABSN/A

Net Income (TTM)

BBOT$-182M

SABS$2M

FCF (TTM)

BBOT$-194M

SABS$-57M

EPS (TTM)

BBOT-$2.27

SABS$0.00

ROE (TTM)

BBOT-4690.0%

SABS15.2%

ROA (TTM)

BBOT-4217.0%

SABS12.5%

ROIC (TTM)

BBOT-4690.0%

SABS14.6%

Cash

BBOT$54M

SABS$8M

Debt

BBOT$0

SABS$3M

Net Cash/Debt

BBOT$54M

SABS$5M

Current Ratio (TTM)

BBOT4.69x

SABS9.22x

Quick Ratio (TTM)

BBOT4.38x

SABS8.93x

Debt/Equity (TTM)

BBOT0.00x

SABS0.01x

Debt/Assets (TTM)

BBOT0.0%

SABS0.0%

Interest Coverage (TTM)

BBOTN/A

SABSN/A

Net Debt/EBITDA (TTM)

BBOT0.00x

SABS0.00x

Beta

BBOT0.67

SABS0.80

52W Performance

BBOT-72.5%

SABS27.4%

YTD Performance

BBOT-73.1%

SABS-21.0%

% from 52W High

BBOT-77.7%

SABS-42.1%

% from 52W Low

BBOT1.2%

SABS41.9%

Asset Turnover (TTM)

BBOT0.00x

SABS0.02x

FCF Yield (TTM)

BBOT-73.1%

SABS-25.2%

Earnings Yield (TTM)

BBOT-68.7%

SABS1.1%

Dividend Yield (TTM)

BBOTN/A

SABSN/A

Rule of 40

BBOT0.0

SABS0.0

EV/GP/RG

BBOTN/A

SABSN/A

Ticker research

View BBOT research View SABS research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	SABS SAB Biotherapeutics Inc
Market & Valuation
Market Cap	$265M	$228M
Enterprise Value	$211M	$223M
Price	$3.31	$2.98
P/E Ratio	N/A	20.43x
P/S Ratio	0.00x	204.97x
EV/Sales	0.00x	201.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.26x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	540.3%	13369.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-182M	$2M
FCF (TTM)	$-194M	$-57M
EPS (TTM)	-$2.27	$0.00
ROE (TTM)	-4690.0%	15.2%
ROA (TTM)	-4217.0%	12.5%
ROIC (TTM)	-4690.0%	14.6%
Financial Health
Cash	$54M	$8M
Debt	$0	$3M
Net Cash/Debt	$54M	$5M
Current Ratio (TTM)	4.69x	9.22x
Quick Ratio (TTM)	4.38x	8.93x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.80
52W Performance	-72.5%	27.4%
YTD Performance	-73.1%	-21.0%
% from 52W High	-77.7%	-42.1%
% from 52W Low	1.2%	41.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.1%	-25.2%
Earnings Yield (TTM)	-68.7%	1.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View SABS research

Valuation

P/E Ratio

SABS

20.43x

P/S Ratio

BBOT

0.00x

SABS

204.97x

EV/FCF

SABS

-3.88x

BBOT

-1.09x

Growth & revenue

Forward Revenue Growth

SABS

13369.8%

BBOT

540.3%

Profitability & performance

Gross Margin

BBOT

0.0%

SABS

0.0%

ROE

SABS

15.2%

BBOT

-4690.0%

FCF Yield %

SABS

-25.2%

BBOT

-73.1%

52-Week Performance

SABS

27.4%

BBOT

-72.5%

Detailed metrics comparison

BBOT

BridgeBio Oncology Therapeutics Inc

SABS

SAB Biotherapeutics Inc

Market Cap

BBOT$265M

SABS$228M

Enterprise Value

BBOT$211M

SABS$223M

Price

BBOT$3.31

SABS$2.98

P/E Ratio

BBOTN/A

SABS20.43x

P/S Ratio

BBOT0.00x

SABS204.97x

EV/Sales

BBOT0.00x

SABS201.14x

EV/EBITDA

BBOT0.00x

SABS0.00x

P/B Ratio

BBOT0.97x

SABS1.26x

P/FCF Ratio

BBOTN/A

SABSN/A

EV/FCF

BBOT-1.09x

SABS-3.88x

PEG Ratio

BBOTN/A

SABSN/A

Forward P/E (NTM)

BBOTN/A

SABSN/A

Forward P/S (NTM)

BBOTN/A

SABSN/A

Revenue (TTM)

BBOT$0

SABS$0

Revenue Growth (YoY)

BBOTN/A

SABSN/A

Forward Rev Growth

BBOT540.3%

SABS13369.8%

Gross Margin (TTM)

BBOT0.0%

SABS0.0%

Operating Margin (TTM)

BBOT0.0%

SABS0.0%

EBITDA Margin (TTM)

BBOT0.0%

SABS0.0%

Net Margin (TTM)

BBOT0.0%

SABS0.0%

FCF Margin (TTM)

BBOTN/A

SABSN/A

Net Income (TTM)

BBOT$-182M

SABS$2M

FCF (TTM)

BBOT$-194M

SABS$-57M

EPS (TTM)

BBOT-$2.27

SABS$0.00

ROE (TTM)

BBOT-4690.0%

SABS15.2%

ROA (TTM)

BBOT-4217.0%

SABS12.5%

ROIC (TTM)

BBOT-4690.0%

SABS14.6%

Cash

BBOT$54M

SABS$8M

Debt

BBOT$0

SABS$3M

Net Cash/Debt

BBOT$54M

SABS$5M

Current Ratio (TTM)

BBOT4.69x

SABS9.22x

Quick Ratio (TTM)

BBOT4.38x

SABS8.93x

Debt/Equity (TTM)

BBOT0.00x

SABS0.01x

Debt/Assets (TTM)

BBOT0.0%

SABS0.0%

Interest Coverage (TTM)

BBOTN/A

SABSN/A

Net Debt/EBITDA (TTM)

BBOT0.00x

SABS0.00x

Beta

BBOT0.67

SABS0.80

52W Performance

BBOT-72.5%

SABS27.4%

YTD Performance

BBOT-73.1%

SABS-21.0%

% from 52W High

BBOT-77.7%

SABS-42.1%

% from 52W Low

BBOT1.2%

SABS41.9%

Asset Turnover (TTM)

BBOT0.00x

SABS0.02x

FCF Yield (TTM)

BBOT-73.1%

SABS-25.2%

Earnings Yield (TTM)

BBOT-68.7%

SABS1.1%

Dividend Yield (TTM)

BBOTN/A

SABSN/A

Rule of 40

BBOT0.0

SABS0.0

EV/GP/RG

BBOTN/A

SABSN/A

Ticker research

View BBOT research View SABS research

Metric	BBOT BridgeBio Oncology Therapeutics Inc	SABS SAB Biotherapeutics Inc
Market & Valuation
Market Cap	$265M	$228M
Enterprise Value	$211M	$223M
Price	$3.31	$2.98
P/E Ratio	N/A	20.43x
P/S Ratio	0.00x	204.97x
EV/Sales	0.00x	201.14x
EV/EBITDA	0.00x	0.00x
P/B Ratio	0.97x	1.26x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.09x	-3.88x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	540.3%	13369.8%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-182M	$2M
FCF (TTM)	$-194M	$-57M
EPS (TTM)	-$2.27	$0.00
ROE (TTM)	-4690.0%	15.2%
ROA (TTM)	-4217.0%	12.5%
ROIC (TTM)	-4690.0%	14.6%
Financial Health
Cash	$54M	$8M
Debt	$0	$3M
Net Cash/Debt	$54M	$5M
Current Ratio (TTM)	4.69x	9.22x
Quick Ratio (TTM)	4.38x	8.93x
Debt/Equity (TTM)	0.00x	0.01x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.67	0.80
52W Performance	-72.5%	27.4%
YTD Performance	-73.1%	-21.0%
% from 52W High	-77.7%	-42.1%
% from 52W Low	1.2%	41.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.02x
FCF Yield (TTM)	-73.1%	-25.2%
Earnings Yield (TTM)	-68.7%	1.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BBOT research	View SABS research